Clinical Chemistry Email Content Delivery
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 51: 922-923, 2005; 10.1373/clinchem.2005.048231
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (1)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ferré, N.
Right arrow Articles by Joven, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ferré, N.
Right arrow Articles by Joven, J.
Related Collections
Right arrow General Clinical Chemistry
Right arrow Lipids, Lipoproteins, and Cardiovascular Risk Factors
(Clinical Chemistry. 2005;51:922-923.)
© 2005 American Association for Clinical Chemistry, Inc.

Letters to the Editor

Comparison of Paraoxonase 1 Measurements in Serum and in Lithium-Heparin-Anticoagulated Plasma Samples

Natàlia Ferré1, Jordi Camps1,a, Judit Marsillach1, Bharti Mackness2, Mike Mackness2, Blai Coll1, Mònica Tous1 and Jorge Joven1

1 Centre de Recerca Biomèdica, Hospital Universitari de Sant Joan, Institut de Recerca en Ciències, de la Salut, Reus, Catalunya, Spain
2 University Department of Medicine, Manchester Royal Infirmary, Manchester, United Kingdom

aAddress correspondence to this author at: Centre de Recerca Biomèdica, Hospital Universitari de Sant Joan, Institut de Recerca en Ciències de la Salut, C/. Sant Joan s/n, 43201-Reus, Catalunya, Spain. Fax 34-977-312569; e-mail jcamps@grupsagessa.com.

The first 20% of the full text of this article appears below.


To the Editor:

Paraoxonase 1 (PON1) is a HDL-associated enzyme that catalyzes the hydrolysis of lipid peroxides in LDL and HDL and has been postulated as a member of the plasma antioxidant system. Decreased PON1 activity has been associated with atherosclerosis in persons with diabetes mellitus, familial hypercholesterolemia, and renal disease (1)(2).

Serum is the preferred sample for PON1 measurement because this enzyme requires calcium for both activity and stability. The presence of calcium chelators such as EDTA or citrate as anticoagulants inhibits PON1 activity (3). This is a serious limitation in retrospective studies, in which serum is not always available. Moreover, in studies on experimental animals, in which the amount of blood collected is often minimal, it is more convenient to use anticoagulants because the recovery of plasma is generally higher than that of serum and there is no interference by the clotting process.

Lithium heparin is an anticoagulant . . . [Full Text of this Article]




The following articles in journals at HighWire Press have cited this article:


Home page
 Clin. Chem.Home page
M. M. Murphy, J. Marsillach, J. Camps, J. Fernandez-Ballart, B. Mackness, M. Mackness, N. Ferre, and J. Joven
Influence of PON1 Polymorphisms on the Association between Serum Paraoxonase 1 and Homocysteinemia in a General Population.
Clin. Chem., April 1, 2006; 52(4): 781 - 782.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 by the American Association for Clinical Chemistry.